(LMNL) – StreetInsider.com Reports
-
Liminal BioSciences (LMNL) Obtains Interim Order for Proposed Arrangement with Structured Alpha LP
-
SALP will acquire all issued and outstanding common shares of Liminal BioSciences (LMNL)
-
Liminal BioSciences (LMNL) Provides R&D Update
-
U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.24%
-
Liminal BioSciences (LMNL) Confirms Receipt of Unsolicited Non-Binding Transaction Proposal
-
Thomvest Submits Proposal To Acquire Liminal Biosciences (LMNL) On An All Cash Basis for $7.50 Per Share
-
Liminal BioSciences (LMNL) Regains Nasdaq Compliance
-
Liminal BioSciences (LMNL) Announces 1:10 Reverse Stock Split
-
Liminal BioSciences (LMNL) Announces Termination of Legacy CDMO Contract
-
Liminal BioSciences (LMNL) Announces Discontinuation of Fezagepras Development
-
Liminal BioSciences (LMNL) Reports Q4 Results
-
Liminal BioSciences (LMNL) Reports No Safety Findings in Phase 1 Study of fezagepras
-
Liminal BioSciences (LMNL) Receives NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement
-
Liminal BioSciences (LMNL) Announces Strategic Priorities For 2022
-
Liminal BioSciences (LMNL) Announces Sale of Priority Review Voucher for $105M
-
H.C. Wainwright Downgrades Liminal BioSciences, Inc. (LMNL) to Neutral
-
Liminal BioSciences (LMNL) Announces Signature of Share Purchase Agreement for sale of Remaining Plasma-derived Business with Kedrion
-
Pre-Open Stock Movers 06/07: (LMNL) (USCR) (QTS) Higher; (MOSY) (MGI) Lower (more...)
-
Liminal BioSciences (LMNL) Announces FDA Approval for its Biologics License Application for Ryplazim
-
Liminal BioSciences (LMNL) Halted, News Pending
-
Piper Sandler Downgrades Liminal BioSciences, Inc. (LMNL) to Neutral
-
Liminal BioSciences (LMNL) ends plans to move fezagepras into Phase II clinical study in Idiopathic Pulmonary Fibrosis and phase Ia/IIb study in Hypertriglyceridemia
-
Liminal BioSciences (LMNL) Enters into Agreement with Kedrion to Divest Its Plasma Collection and Plasma-Derived Therapeutics Business
-
UPDATE: H.C. Wainwright Starts Liminal BioSciences, Inc. (LMNL) at Buy
-
Liminal BioSciences (LMNL) Receives FDA Approval for its US-based Plasma Collection Center
-
Liminal BioSciences (LMNL) Halted on LUDP, Up 40%
-
Pre-Open Stock Movers 12/21: (AGIO) (RP) (NK) (AJRD) (CLVS) (QURE) (More...)
-
Piper Sandler Starts Liminal BioSciences, Inc. (LMNL) at Overweight
-
Liminal BioSciences (LMNL) Reports First Subject Dosed in Phase 1 Multiple Ascending Dose Clinical Trial of Fezagepras
-
Liminal BioSciences (LMNL) Reports Q3 Revenues of $600K
-
Liminal BioSciences (LMNL) Provides Update on Progress on BLA for Ryplazim, FDA Assigns PDUFA Target Action Date of March 5
-
Liminal BioSciences (LMNL) Reports Resubmission of Biologics License Application to FDA for Ryplazim (plasminogen) for Treatment of Congenital Plasminogen Deficiency
-
Pre-Open Stock Movers 08/24: (NNBR) (XBIT) (TSLA) Higher; (ONTX) (MWK) Lower (more...)
-
Convalescent Plasma Stocks Surge as FDA Issue Emergency Use Authorization
-
Liminal BioSciences (LMNL) Joins CoVIg Plasma Alliance to Contribute to Development of Potential New COVID-19 Therapy
-
Liminal BioSciences (LMNL) Commences Collection of Convalescent Plasma from COVID-19 Recovered Donors
-
Liminal BioSciences (LMNL) Comments on Unusual Market Activity, Not Aware of any Undisclosed Material Change
Back to LMNL Stock Lookup